ARC-166 PET agent guides first ARC-706 patient dose
Archeus has started a phase I study pairing the Y-86 ARC-166 diagnostic agent with Y-90 ARC-706 therapy in metastatic cancer patients receiving immune checkpoint inhibitors.
Archeus Technologies has dosed the first patient in a phase I study of ARC-706 and its companion diagnostic ARC-166 in metastatic cancer patients receiving immune checkpoint inhibition therapies. The first-in-human study is being conducted at the University of Wisconsin Carbone Cancer Center, according to the company.
The trial pairs Y-86 ARC-166 PET imaging with Y-90 ARC-706 radiopharmaceutical therapy. Participants receive intravenous ARC-166 first for dosimetry and patient selection before receiving ARC-706, Archeus said.
Study endpoints include safety, biodistribution, pharmacokinetics, and the potential for ARC-706 to augment anti-tumor immune response. The trial is also designed to determine an optimal phase Ib dose and explore changes in cancer-related biomarkers.
ARC-706 uses Archeus’ NM600 tumor-targeting platform with the beta-emitting isotope yttrium-90. ARC-166 uses the PET isotope yttrium-86 as the imaging component of the theranostic pair.
Archeus is developing the therapy for combination use with validated immunotherapies across multiple oncology indications. The study is enrolling patients with metastatic cancer who are receiving immune checkpoint inhibitors, according to the University of Wisconsin School of Medicine and Public Health.
Preclinical studies showed tumor-selective uptake of ARC-706 in multiple cancers treated with immune checkpoint inhibitors, according to the company. Archeus also said imaging-guided dosing based on ARC-166 results increased response rates and response durability in preclinical work.
The company previously said ARC-706 and ARC-166 received FDA investigational new drug clearances in October 2024. In a June 2025 release, Archeus said it planned to advance the 2 assets together as a theranostic pair into clinical development.
UW said Archeus has ties to the University of Wisconsin-Madison, UW Health’s Isthmus Project, and the Wisconsin Alumni Research Foundation. The company has described the University of Wisconsin collaboration as supporting radiochemistry, imaging, dosimetry, and analytical work.
The current trial remains an early-phase study. Archeus said the treatment and imaging approach is being evaluated in patients continuing immunotherapy despite signs of disease progression.
Company:Archeus Technologies
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
UPatch monitors fetal blood flow for up to 6 hours
A Nature Biotechnology study tested the abdomen-worn device against handheld ultrasound in 62 pregnancies and used continuous monitoring in 52 pregnant women.
Pediatric ED imaging gaps persist by race and insurance status
A cohort study of 857,034 pediatric ED visits found that stronger hospital pediatric capability was not associated with narrower imaging-use differences by race, ethnicity, or insurance status.
Chest X-ray AI study exposes lung cancer detection gaps
A head-to-head study of 7 commercial AI devices found sensitivity ranged from 20.8% to 77.8% for lung cancer detection on chest X-rays.
MRI radiomics score flags aggressive colorectal cancer subtype
The multicenter study found an MRI-based machine-learning radiomics score predicted CMS4 colorectal cancer and stratified recurrent metastasis risk.
Contrast tied to higher AKI risk in neonatal ICU study
The retrospective study found higher acute kidney injury rates in neonates exposed to iodinated contrast media, although most cases were stage 1.
Quantum BioPharma reports early PET tracer signal in MS study
The ongoing MGH study is evaluating [18F]3F4AP PET imaging for demyelinated neurons with intact axons in patients with multiple sclerosis.
PSA screening review finds fewer deaths, more diagnoses
The updated review found PSA screening likely reduces prostate cancer deaths, but evidence remains unclear for newer screening strategies combining PSA, kallikrein testing, and MRI.
Stage 4 breast cancer diagnoses rise over decade
A cohort study of 761,471 people found de novo stage 4 breast cancer incidence increased by 1.2% per year from 2010 to 2021.
SIR backs genicular artery embolization for knee osteoarthritis
The Society of Interventional Radiology issued a position statement supporting genicular artery embolization for symptomatic knee osteoarthritis.
Fluoride, lead co-exposure linked to lower youth BMD
Researchers analyzed NHANES data from 2,378 U.S. children and adolescents who underwent DEXA scans from 2013 to 2016.
Stanford project aims to make MR lymphangiography faster
Stanford Medicine received up to $3.9M from ARPA-H to advance MR lymphangiography. Andreas Loening, MD, PhD, will lead work on faster scans, lymphatic-specific contrast agents, and contrast-free flow assessment.
Bayer PET tracer meets cardiac amyloidosis endpoints
Bayer reported positive topline phase 3 REVEAL results for I-124 evuzamitide, an investigational PET/CT radiotracer for suspected cardiac amyloidosis. The study met its sensitivity and specificity endpoints.